Zentek Ltd. (ZTEK) files 6-K on H1N1 influenza countermeasure

Rhea-AI Filing Summary

Zentek Ltd. filed a Form 6-K as a foreign private issuer. The filing mainly serves as a cover to furnish an attached press release as an exhibit.

The exhibit, dated September 18, 2025, provides a preliminary update on Zentek’s influenza countermeasure candidate developed using its multivalent aptamer technology against H1N1 seasonal influenza.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41310

ZENTEK LTD.

(Registrant)

24 Corporate Court

Guelph, Ontario N1G 5G5 Canada

(Address of Principal Executive Offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☐            Form 40-F  ☒

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ZENTEK LTD.
	(Registrant)
Date: September 18, 2025	By	/s/ Wendy Ford
		Wendy Ford
		Chief Financial Officer

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	Press Release dated September 18, 2025 - Zentek Provides a Preliminary Update on Influenza Countermeasure Candidate Developed Using the Multivalent Aptamer Technology against H1N1 (Seasonal Influenza)

FAQ

What does Zentek Ltd. (ZTEK) report in this Form 6-K?

Zentek Ltd. uses this Form 6-K to submit an exhibit containing a press release. The release provides a preliminary update on its influenza countermeasure candidate using multivalent aptamer technology against H1N1 seasonal influenza, dated September 18, 2025.

What medical area does Zentek Ltd. (ZTEK) address in this update?

The update focuses on an influenza countermeasure candidate. Specifically, Zentek reports on a candidate developed using multivalent aptamer technology targeting H1N1 seasonal influenza, indicating work in infectious disease prevention or treatment related to seasonal flu strains.

What technology is highlighted by Zentek Ltd. (ZTEK) in the exhibit?

Zentek highlights its multivalent aptamer technology in connection with an influenza countermeasure candidate. The exhibit description notes this technology is being applied against H1N1 seasonal influenza, suggesting a platform-based approach to developing medical countermeasures.

Which influenza strain is Zentek Ltd. (ZTEK) developing a countermeasure for?

The company’s preliminary update concerns a countermeasure candidate against H1N1 seasonal influenza. The exhibit description explicitly states the candidate is developed using multivalent aptamer technology to address H1N1, a common subtype associated with seasonal flu outbreaks.

Who signed Zentek Ltd.’s (ZTEK) September 2025 Form 6-K?

The Form 6-K was signed on behalf of Zentek Ltd. by Wendy Ford. She is identified as the company’s Chief Financial Officer, and the signature date given in the document is September 18, 2025, confirming her authorization of the submission.

Where can investors find detailed information on Zentek Ltd.’s influenza candidate?

Detailed information is contained in Exhibit 99.1 to the Form 6-K. This exhibit is a press release titled “Zentek Provides a Preliminary Update on Influenza Countermeasure Candidate Developed Using the Multivalent Aptamer Technology against H1N1 (Seasonal Influenza).”